End Drug Shortages Alliance Releases Market Assessment for Drugs Impacted by Manufacturing Plant Closure

·3 min read

IRVING, Texas, May 17, 2022--(BUSINESS WIRE)--The End Drug Shortages Alliance today announced it has released a market analysis of products affected by a recent Teva pharmaceutical manufacturing plant closure in Irvine, Calif. The closure is expected to potentially impact approximately 25 pharmaceutical injectables that were manufactured at the plant, including five essential medications where Teva supplied greater than 15% of the market in the last year. These products treat a variety of disease states, including cancer, adult and pediatric diabetes and pancreatic neuroendocrine tumors. The report can be accessed here.

"We are surfacing the information and amplifying it so that all industry stakeholders are aware and can prepare for an unanticipated disruption," said Terri Lyle Wilson RPh, CMTM, End Drug Shortages Alliance vice chair and director of pharmacy, supply chain services for Children’s Hospital Association. "Information shared in this report highlights the level of transparency that is required across the supply chain to successfully navigate drug shortages."

Transparency in the supply chain is one of three key objectives of the Alliance, and the Alliance has a dedicated committee, representing all aspects of the supply chain, focused on improvements in this area. All Alliance workstreams are aligned to the organization’s objectives, including:

  • Transparency and redundancy, including an early alert system for drug shortages.

  • Quality, including identifying and prioritizing what medications are needed clinically in urgent situations.

  • Production of additional supply, in part by gaining commitment from manufacturers of essential medications to provide the Alliance with advanced notice when exiting the market or reducing supply by a significant amount.

The report assesses products that have greater than 15% market share, lists additional suppliers currently in the market, offers an estimated level of impact for each medication and outlines mitigation strategies to navigate potential supply challenges. The report also includes recommendations for key industry and regulatory stakeholders for practicing stewardship during ordering, prescribing and administering these products and encouraging manufacturers and wholesalers to proactively manage production output and order fulfillment capacity to meet evolving market need.

It is the first analysis offered by the newly formed Alliance, which was launched in November to shed light on the causes of drug shortages and offer solutions for the persistent issue of supply disruption in pharmacy. More than 70 organizations have joined to date and have begun work in identifying essential medications at risk for supply disruption and creating a platform to share best practices in drug shortage stewardship.

To learn more about the End Drug Shortages Alliance, email Media@EndDrugShortagesAlliance.com.

About End Drug Shortages Alliance

The End Drug Shortages Alliance is a collaboration of health care industry stakeholders, including providers, group purchasing organizations, manufacturers, distributors and other industry thought leaders dedicated to solving the pharmaceutical supply challenges that disrupt access to essential medications in the U.S. We prioritize initiatives focused on transparency, quality, redundancy and production of additional supply to achieve undisrupted access to essential medications for health care providers and patients.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517006055/en/


Meagan Finucane
(708) 407-5497